• In early February 2026, IDEXX Laboratories reported past fourth-quarter and full-year 2025 results showing double-digit gains in revenue and earnings, alongside initial 2026 guidance calling for US$4.63–US$4.72 billion in sales and earnings per share of US$14.29–US$14.80.
• Management highlighted that growth was powered by Companion Animal Group Diagnostics, including record placements of new inVue Dx instruments and expanding Cancer Dx offerings, underscoring the impact of recent veterinary diagnostic innovations.
• With the shares recently showing a 4.01% seven-day decline but a slight 0.10% one-day rise, we’ll explore how IDEXX’s innovation-led CAG Diagnostics momentum shapes its investment narrative.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is IDEXX Laboratories' Investment Narrative?

To own IDEXX, you need to believe in a premium, innovation-heavy veterinary diagnostics franchise that can keep Companion Animal Group instruments and recurring tests at the heart of practice workflows. The latest 2025 results reinforced that story, with solid double-digit gains and high-quality margins, but the new 2026 guidance points to a cooler pace of growth than the prior year. That helps explain the recent pullback, even as the stock is still priced richly on earnings multiples and trades above some cash flow based estimates. Near term, the key catalyst remains whether inVue Dx and expanding Cancer Dx usage can sustain robust recurring revenues without requiring another surge of record instrument placements. The biggest risks look tied to the high valuation, elevated debt and any stumble against those new guidance ranges.

However, investors should also weigh how IDEXX’s premium valuation amplifies execution risk. IDEXX Laboratories' share price has been on the slide but might be up to 22% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Five Simply Wall St Community fair value views span from about US$337 to US$850, underlining how far apart individual expectations can be. Set against management’s more measured 2026 guidance and the stock’s rich earnings multiple, these differing opinions invite you to compare upside hopes with the very real risk that any miss on CAG Diagnostics momentum could prompt a sharper reassessment of IDEXX’s premium profile.

Explore 5 other fair value estimates on IDEXX Laboratories - why the stock might be worth as much as 32% more than the current price!

Build Your Own IDEXX Laboratories Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your IDEXX Laboratories research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 30 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.